1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/16/2024 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 73.7% | Truist Securities | Joon Lee | $36 → $42 | Maintains | Buy | Get Alert |
01/02/2024 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 15.8% | HC Wainwright & Co. | Swayampakula Ramakanth | $34 → $28 | Maintains | Buy | Get Alert |
12/13/2023 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 57.15% | Canaccord Genuity | Edward Nash | $37 → $38 | Maintains | Buy | Get Alert |
11/06/2023 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 57.15% | Truist Securities | Joon Lee | $29 → $38 | Upgrade | Hold → Buy | Get Alert |
11/02/2023 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 40.61% | HC Wainwright & Co. | Swayampakula Ramakanth | $32 → $34 | Maintains | Buy | Get Alert |
10/02/2023 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 19.93% | Truist Securities | Joon Lee | → $29 | Reiterates | Hold → Hold | Get Alert |
08/25/2023 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 44.75% | Canaccord Genuity | Edward Nash | $34 → $35 | Maintains | Buy | Get Alert |
08/03/2023 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 28.21% | Piper Sandler | David Amsellem | $27 → $31 | Maintains | Overweight | Get Alert |
08/03/2023 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 19.93% | Truist Securities | Gregory Fraser | $26 → $29 | Maintains | Hold | Get Alert |
08/03/2023 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 32.34% | HC Wainwright & Co. | Swayampakula Ramakanth | $30 → $32 | Maintains | Buy | Get Alert |
05/26/2023 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 7.53% | Truist Securities | Gregory Fraser | $28 → $26 | Maintains | Hold | Get Alert |
05/04/2023 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 24.07% | HC Wainwright & Co. | Swayampakula Ramakanth | $30 → $30 | Reiterates | → Buy | Get Alert |
04/11/2023 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 3.39% | SVB Leerink | Roanna Ruiz | → $25 | Initiates | → Market Perform | Get Alert |
04/04/2023 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 11.66% | Piper Sandler | David Amsellem | → $27 | Initiates | → Overweight | Get Alert |
03/08/2023 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 32.34% | Canaccord Genuity | Edward Nash | $33 → $32 | Maintains | Buy | Get Alert |
03/01/2023 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 24.07% | HC Wainwright & Co. | Swayampakula Ramakanth | → $30 | Reiterates | → Buy | Get Alert |
02/15/2023 | CORT | Buy Now | Corcept Therapeutics | $24.18 | -9.02% | Jefferies | Dennis Ding | $35 → $22 | Downgrade | Buy → Hold | Get Alert |
12/09/2022 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 24.07% | HC Wainwright & Co. | Swayampakula Ramakanth | $33 → $30 | Maintains | Buy | Get Alert |
11/08/2022 | CORT | Buy Now | Corcept Therapeutics | $24.18 | 15.8% | Truist Securities | Gregory Fraser | $30 → $28 | Maintains | Hold | Get Alert |
The latest price target for Corcept Therapeutics (NASDAQ: CORT) was reported by Truist Securities on February 16, 2024. The analyst firm set a price target for $42.00 expecting CORT to rise to within 12 months (a possible 73.70% upside). 14 analyst firms have reported ratings in the last year.
The latest analyst rating for Corcept Therapeutics (NASDAQ: CORT) was provided by Truist Securities, and Corcept Therapeutics maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corcept Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corcept Therapeutics was filed on February 16, 2024 so you should expect the next rating to be made available sometime around February 16, 2025.
While ratings are subjective and will change, the latest Corcept Therapeutics (CORT) rating was a maintained with a price target of $36.00 to $42.00. The current price Corcept Therapeutics (CORT) is trading at is $24.18, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.